What lies ahead for Melbourne’s biotechnology, medical technology and pharmaceutical industry in 2019? BioMelbourne Network’s annual “Hot or Not” discussion explores the global trends for the coming year with 4 speakers each presenting a short “snap shot” of what is HOT and what is NOT going into 2019 in their area of interest and expertise.
Topics for discussion include:
AI & IP – Raffaele Calabrese, Patent Attorney, Phillips Ormonde Fitzpatrick
Exosomes – Dr Ian Dixon, CEO & Founder, Exopharm Ltd (ASX-EX1)
Consumer Health – Swisse Wellness
JP Morgan conference insight – Market/Sector Trends – Sam Cobb, Managing Director & Chief Executive Officer, Adalta
When
Thursday – 7 February 2019
Time
3:45pm Registrations
4:00–5:25pm Presentations and Q&A
Networking until 6:30pm
Where
Phillips Ormonde Fitzpatrick, Level 16, 333 Collins Street, Melbourne
Cost
BioMelbourne Network Members: $65
Non-members: $130
(prices include GST)
Check if your organisation is a member
Raffaele Calabrese, Patent Attorney, Phillips Ormonde Fitzpatrick
Raffaele has a background in electrical and electronic engineering, and a master’s degree in engineering specialising in information technology and telecommunications. He has had over ten years of professional experience in protecting inventions relating to ICT, software and engineering.
Raffaele began his intellectual property (IP) career in 2005 as a Technical Assistant with an IP firm in Adelaide. In 2007, he moved to Melbourne and joined a large IP firm, where he specialised in drafting and prosecuting patent applications in Australia and overseas. During this time, he also gained experience in assisting Australian and international clients with obtaining trade mark and design protection.
Raffaele’s background provides him with an in depth understanding of a wide range of electronic and mechanical inventions. He also has experience in protecting computer implemented inventions, including Fin Tech inventions, mining, energy and medical technologies.
Dr Ian Dixon, CEO & Founder, Exopharm Ltd
Dr Dixon brings to the Exopharm Board an extensive technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development.
In 2011, Dr Dixon Co-Founded Cynata Inc, a company that is progressing the commercialisation of what has become the Cymerus technology of ASX-listed Cynata Therapeutics Ltd (ASX-CYP).
Dr Dixon is also a non-executive director of Noxopharm Ltd (ASX-NOX); a founder of Nyrada Inc.; a co-inventor of Nyrada drug NYX-330; founder of Genscreen Pty Ltd (2003-2018) and; former director of Cell Therapies Pty Ltd. Dr Dixon currently also serves as a part-time executive director of Medigard Ltd (ASX:MGZ).
Dr Dixon is a co-inventor of the LEAP Technology now owned by Exopharm.
Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.
Sam Cobb, Managing Director & Chief Executive Officer, Adalta
Sam is the founding CEO of AdAlta and has over fifteen years’ experience in business development and commercialisation of early stage scientific technologies.
Prior to AdAlta, Sam was the Business Development Director at the Co-operative Research Centre for Diagnostics. Sam has also worked for the biotech start up companies Sensologix Inc and Nephrogenix Pty Ltd and at the University of Queensland’s technology commercialisation companies, Uniquest Pty Ltd and IMBcom Pty Ltd.
Sam has a Bachelor of Science, a Masters of Intellectual Property Law and has completed the Australian Institute of Company Directors course.
